Online citations, reference lists, and bibliographies.
← Back to Search

Negative Antibody Response To Long-term Treatment Of Facial Spasm With Botulinum Toxin.

R. Gonnering
Published 1988 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Over a period of 163 weeks, 223 injections of botulinum A toxin were administered to 38 patients with facial spasm syndromes. The maximum cumulative toxin dose was 553 units, the maximum number of injections in any given patient was 16, and the maximum dosage of any given injection was 52.5 units. Sera from these patients showed no antibody production when measured with a standard mouse lethality bioassay.
This paper references
10.1016/0002-9394(85)90228-4
Treatment of blepharospasm with botulinum toxin.
E. A. Tsoy (1985)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1016/S0161-6420(87)33338-X
Effectiveness of botulinum toxin therapy for essential blepharospasm.
P. Engstrom (1987)
10.1212/WNL.37.1.123
Visual electrical evoked potentials
L. Dorfman (1987)
10.1128/JB.79.3.372-378.1960
Studies on immunity to toxins of Clostridium botulinum. VI. Purification and detoxification of type D toxin and the immunological response to toxoid.
M. A. Cardella (1960)
10.1001/ARCHOPHT.1985.01050090057031
Hemifacial spasm treated with botulinum A toxin injection.
P. Savino (1985)
10.1093/INFDIS/150.3.407
Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.
C. H. Hatheway (1984)
Botulinum toxin injection of eye muscles to correct strabismus.
A. B. Scott (1981)
10.1212/WNL.37.4.616
Botulinum A toxin for cranial‐cervical dystonia
J. Jankovic (1987)
10.1212/WNL.35.10.1499
Blepharospasm, Meige syndronfie, and hemifacial Spasm
J. Mauriello (1985)
10.1097/00002826-198610000-00002
Botulinum injection therapy for blepharospasm: a review and report of 75 patients.
D. Cohen (1986)
10.1016/S0161-6420(87)33337-8
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
J. Mauriello (1987)
Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid.
M. A. Fiock (1962)
10.1016/S0161-6420(86)33785-0
The use of botulinum toxin in the medical management of benign essential blepharospasm.
K. I. Perman (1986)
10.1001/ARCHOPHT.1984.01040031184014
Treatment of blepharospasm with botulinum toxin. A preliminary report.
B. Frueh (1984)
Treatment of Torticollis with Injections of Botulinum Toxin
P. Greene (1987)
10.1016/0002-9394(86)90601-X
Absence of antibody production in patients treated with botulinum A toxin.
A. W. Biglan (1986)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
10.1097/00002341-198601060-00005
Treatment of Hemifacial Spasm with Botulinum A Toxin: Results and Rationale
R. Gonnering (1986)



This paper is referenced by
10.1053/SDER.2001.24423
Botulinum toxin type A (BOTOX) for treatment of migraine.
W. Binder (2002)
10.1006/exnr.1997.6580
Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences
H. Göschel (1997)
10.1007/978-3-642-85173-5_6
Clinical use of botulinum neurotoxins.
F. Cardoso (1995)
10.1136/jnnp.59.6.601
Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
G. Sheean (1995)
10.3109/08820539209065092
Botulinum toxin in ophthalmology
J. Holmes (1992)
10.1016/S0966-6362(99)00054-5
Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.
H. Graham (2000)
10.1046/J.1524-4725.2003.29129.X
Complications, Adverse Reactions, and Insights With the Use of Botulinum Toxin
A. Klein (2003)
10.1016/S0161-6420(13)31718-7
Timing of amblyopia therapy.
E. Campos (1994)
10.1053/MDA.2001.25964
Complications and adverse reactions with the use of botulinum toxin.
A. Klein (2002)
10.1056/NEJM199104253241707
Therapeutic uses of botulinum toxin.
J. Jankovic (1991)
10.1007/s00115-003-1611-5
Antikörpervermitteltes Versagen der Botulinum-Toxin-Therapie
D. Dressler (2003)
10.1097/00004397-200404430-00014
Pharmacology and Clinical Applications of Botulinum Toxins A and B
M. Thakker (2004)
10.3109/9781841847559.001
Pharmacology, Immunology and Current Developments
Kunio Aoki (2006)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
10.1002/mds.1238
Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy
D. Dressler (2002)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1007/978-3-642-85173-5_5
Immunodiagnosis and immunotherapy of tetanus and botulinum neurotoxins.
J. Middlebrook (1995)
10.1016/S0025-6196(12)64977-5
Treatment of blepharospasm with botulinum toxin.
R. H. Kennedy (1989)
10.1053/SDER.2001.25964
Complications and adverse reactions with the use of botulinum toxin.
A. Klein (2001)
10.1016/0039-6257(91)90207-V
Botulinum A toxin (Oculinum) in ophthalmology.
M. Osako (1991)
10.1016/S0163-7258(96)00091-5
Botulinum toxin as a therapeutic agent.
J. Tsui (1996)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.1016/S0161-6420(93)31384-9
Serum antibody production to botulinum A toxin.
R. Siatkowski (1993)
10.1007/BF00839205
Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use
P. Hambleton (2004)
10.1097/01.iio.0000167160.48750.94
Practical Aspects of Cosmetic Botulinum Toxin
Geva E Mannor (2005)
10.1053/MDA.2002.24423
Botulinum toxin type A (BOTOX) for treatment of migraine.
W. Binder (2001)
10.1016/j.tox.2013.02.006
Botulinum toxins: mechanisms of action, antinociception and clinical applications.
A. Wheeler (2013)
10.1002/mds.20022
Clinical presentation and management of antibody‐induced failure of botulinum toxin therapy
D. Dressler (2004)
10.1097/FAD.0b013e328346f575
Botulinum toxins: adverse effects
C. Anton (2011)
10.1016/j.survophthal.2010.03.008
Review and update of involuntary facial movement disorders presenting in the ophthalmological setting.
A. Ross (2011)
10.1016/S0733-8635(03)00122-0
Complications with the use of botulinum toxin.
A. Klein (2004)
10.1001/ARCHNEUR.1991.00530240057020
Clinical correlates of response to botulinum toxin injections.
J. Jankovic (1991)
See more
Semantic Scholar Logo Some data provided by SemanticScholar